Cardiac hypertrophy after myocardial infarction (MI) is an independent risk factor for heart failure. Regression of cardiac hypertrophy has emerged as a promising strategy in the treatment of MI patients. Here, we have been suggested that heatshock transcription factor 1 (HSF1) is a novel repressor of ischaemia-induced cardiac hypertrophy. Ligation of left anterior descending coronary was used to produce MI in HSF1-deficient heterozygote (KO), HSF1 transgenic (TG) mice and their wild-type (WT) littermates, respectively. Neonatal rat cardiomyocytes (NRCMs) were treated by hypoxia to mimic MI in vitro. The HSF1 phosphorylation was significantly reduced in the infarct border zone of mouse left ventricles (LVs) 1 week after MI and in the hypoxia-treated NRCMs. HSF1 KO mice showed more significant maladaptive cardiac hypertrophy and deteriorated cardiac dysfunction 1 week after MI compared to WT MI mice. Deficiency of HSF1 by siRNA transfection notably increased the hypoxia-induced myocardial hypertrophy in NRCMs. Mechanistically, Janus kinase 2 (JAK2) and its effector, signal transducer and activator of transcription 3 (STAT3) were found to be significantly increased in the LV infarct border zone of WT mice after MI as well as the NRCMs treated by hypoxia. These alterations were more significant in HSF1 KO mice and NRCMs transfected with HSF1
| INTRODUCTION
As a major cause of cardiovascular morbidity and mortality, myocardial infarction (MI) has drawn extensive attention for decades. 1 Post-MI cardiac hypertrophy is an independent risk factor of sudden cardiac death and heart failure, which has emerged as a promising target in the treatment of patients with MI. 2 The underlying molecular mechanisms of cardiac hypertrophy have not fully elucidated yet; thus, effective strategies mitigating the cardiac hypertrophy are still far from the attainment of clinical cure throughout the last decades. Therefore, a better understanding of the molecular mechanisms regulating the hypertrophy-related signalling pathways is important for the development of new therapies to treat pathological cardiac hypertrophy and heart failure after MI.
Heat-shock transcription factor 1 (HSF1) is a transcription factor of the heat-shock genes activated after temperature stress. 3 HSF1
exists in cytoplasm as an inactive monomer in a complex with HSP40/HSP70 and HSP90. 4 Upon stress, phosphorylation of HSF1 on Ser230 positively contributes to the transcriptional activity of HSF1, which was trimerized after dissociating from the chaperone complex. 5 It was demonstrated as a key factor involved in the adaptive mechanism of transition from adaptive cardiac hypertrophy to maladaptive heart failure. 6 Our previous studies indicated that HSF1
functions as an essential intrinsic cardioprotective factor attributing to decreases of pathological cardiac hypertrophy and myocardial fibrosis against ischaemia injury and pressure overload. 7, 8 HSF1 inhibits the pressure overload-induced cardiac hypertrophy and thus maintains the cardiac function through the interaction with signal transducer and activator of transcription 3 (STAT3). 7 STAT3, together with its upstream regulator, Janus kinase 2 (JAK2), has been proved to play detrimental roles in the cardiac hypertrophy and the transition to heart failure. 9, 10 As increasing evidence illustrated that HSF1 is a potential therapeutic target of cardiac hypertrophy, we here have been suggested that by targeting JAK2/STAT3 signalling pathway, HSF1 may open new pharmacological venues for treating cardiac hypertrophy and heart failure after MI to supplement current drugs that target the sympathetic or renin-angiotensin systems.
In this study, using LAD ligation in HSF1 KO and TG mice, together with hypoxic treatment in NRCMs infected with adenovirus of HSF1 SiRNA, we uncovered that deficiency of HSF1 deteriorated cardiac hypertrophy and cardiac dysfunction after MI through enhancing the activity of JAK2/STAT3 signalling. Whereas enhanced HSF1 activation inhibited the cardiac hypertrophy after MI in HSF1 TG mice. Our findings may provide an optional therapeutic strategy to inhibit pathological cardiac remodelling and improve the cardiac function after MI.
| MATERIALS AND METHODS

| Isolation of neonatal rat cardiomyocytes
Primary cultures of neonatal rat cardiac myocytes were prepared as described previously. 8, 11 Briefly, 1-to 2-day-old Sprague Dawley rats were killed by swift decapitation and their hearts were immediately removed under aseptic conditions and placed in ice-cold sterile PBS (calcium-and magnesium-free 
| Echocardiographic measurements
Echocardiography and invasive haemodynamic measurement were performed at baseline and 1 week after sham or LAD ligation surgery. Mice were anesthetized by inhalation of 2% isoflurane.
Transthoracic echocardiographic analysis was performed using an animal-specific instrument (VisualSonics Vevo770, VisualSonics Inc., Canada) as previously described. 
| Invasive haemodynamic test
Haemodynamic assessment was performed by a 1.4 F pressure catheter (SPR 671, Millar Instruments) inserted into the aorta and LV through the right common carotid artery after mice were anesthetized by inhalation of 2% isoflurane. 8, 11 The transducer was connected to Powerlab system (AD Instruments, Castle Hill, Australia).
Cardiac morphological and haemodynamic parameters including LV end-systolic pressure (LVESP), LV end-diastolic pressure (LVEDP) and maximal contraction and relaxation velocity (max dp/dt and min dp/ dt) were record and analysed. (Table S1 ).
| Pathological test
| Western blotting
Total ventricular extracts were prepared from the LV myocardium as described previously. 14 The cytoplasmic and nuclear protein was extracted as previously described. 8 Protein concentrations were measured by BCA (Sigma-Aldrich, USA) assay.
Equal amount of protein extracts was separated with SDS-page and transferred to a nitrocellulose membrane (Millipore, USA).
GAPDH was used for a loading control of total protein. The blots were analysed and quantified by densitometry using ImageJ program.
| Statistical analysis
Data are shown as mean AE SEM. Multiple group comparison was performed by one-way or two-way ANOVA followed by LSD 
| Deficiency of HSF1 aggravated hypoxiainduced myocardial hypertrophy in vitro
Given the reduced HSF1 phosphorylation in hypertrophic hearts under myocardial ischaemia, we next determined whether a decrease in HSF1 phosphorylation promotes hypoxia-induced cardiac hypertrophy. NRCMs were exposed in hypoxic condition for 24 hours to mimic MI in vitro. AdshHSF1 was infected in NRCMs to artificially restrain the expression of HSF1 in the cardiomyocytes (Figure 2A , B). Treatment with hypoxia has no effect on the expression of total HSF1, but significantly inhibited the phosphorylation of HSF1 (Figure 2A, B) . The NRCMs were then subjected to immunostaining using a-MHC primary antibody as shown in Figure 2C . Hypoxia (Table 1) . Furthermore, MI mice also showed a significant decrease in maximal contraction and relaxation velocity (max dp/dt and min dp/dt) vs sham. These haemodynamic alterations were more significant in HSF1 KO mice 1 week after LAD ligation (Table 1) .
Cardiac hypertrophy was further determined by the direct ex vivo measurements and histological analysis in the heart tissues 1 week after MI. Compared to sham mice, MI mice exhibited a significant increase in heart weight/body weight ratio (HW/BW) (Figure 3A) , LV weight/tibial length ratio (LVW/TL) ( Figure 3B ), lung weight/tibia length (LW/TL) ( Figure 3C ) and cross-sectional area (CSA) of cardiomyocytes ( Figure 3D , E). HSF1 KO MI mice showed more significant changes in these direct measurements vs WT MI mice ( Figure 3A-D) . Additionally, elevated ANP and BNP in MI mice vs sham mice were significantly increased in HSF1 KO mice (Figure 3F ). To reveal whether the deterioration of cardiac hypertrophy was a resultant change in the myocardial infarction, we measured the infarct area of the mouse hearts. As shown in Figure 3G , HSF1 KO mice showed similar infarct area 1 week after MI compared to WT mice. The deficiency of HSF1 had no significant effect on the myocardial apoptosis in the LV border zone of MI mice ( Figure 3H,   I ). Collectively, these in vivo data, consistent with the observations in vivo, further supported that HSF1 is necessary for the development of cardiac hypertrophy and the transition to heart failure in the early stage of MI.
| Deficient HSF1 enhanced the activation of JAK2/STAT3 signalling pathway
As JAK2 is critically involved in the cardiac hypertrophy, we measured the phosphorylation of JAK2 in both the MI mouse hearts and the hypoxia-treated NRCMs. We observed that 1 week after MI, the phosphorylation of JAK2 in the infarct border zone of the LV was strikingly increased in the HSF1 KO mice compared with those hearts of the WT mice ( Figure 4A, B) . Similarly, the phosphorylation of JAK2 in hypoxia-treated NRCMs was boosted by 2.9-folds in the NRCMs treated by AdshHSF1 compared with the control NRCMs ( Figure 4D ,E). STAT3 is a key downstream effector of JAK2. We here tested whether the HSF1 deficiency could increase the activity of STAT3 evoked by ischaemia. As shown in Figure 4A , C, increased phosphorylation of STAT3 was also enhanced in the border zone of the LVs of HSF1 KO mouse in vivo. We also found that the phosphorylated STAT3 was significantly increased in the hypoxia-treated NRCMs, which were enhanced by the deficiency of HSF1 (Figure 4D, F) . These findings collectively demonstrated that ablation of HSF1 increased the activation of JAK2/STAT3 signalling pathway.
| Enhanced phosphorylation of HSF1 relieved pathological cardiac hypertrophy induced by LAD ligation in mice
As the deficient HSF1 resulted in a deteriorated cardiac hypertrophy and heart failure, we next explored whether an enhanced phosphorylation of HSF1 abrogates the maladaptive cardiac hypertrophy induced by MI in HSF1 TG mice. The basal cardiac morphology and contractile function were similar between the HSF1 TG mice and their WT littermates through the measurement of echocardiography ( LVAWd, left ventricular anterior wall end-diastolic thickness; EF, ejection fraction; LVIDd, left ventricular internal end-diastolic dimensions; HR, heart rate; LVESP, LV end-systolic pressure; LVEDP, LV end-diastolic pressure; max dp/dt, maximal contraction velocity; min dp/dt, maximal relaxation velocity. and increased EF 1 week after MI compared to WT mice (Table 2) .
Similarly, haemodynamic abnormalities caused by 1-week MI in WT mice were notably mitigated in HSF1 TG mice, implying a improvement of contractile function of LV led by HSF1 overexpression (Table 2) . Figure 5F ). The infarct area of the mouse hearts in HSF1 KO mice was similar compared to WT mice 1 week after MI ( Figure 5G ). The myocardial apoptosis were both significantly and similarly increased in the MI mice in both Wt and HSF1 TG mice (Figure 5H, I ). Together, these in vivo data from HSF1 TG mice further demonstrated that HSF1 is able to inhibit the pathological cardiac hypertrophy and promote the cardiac dysfunction induced by MI.
| DISCUSSION
Although the long-held view has been that cardiac hypertrophy in response to pathological stress including ischaemia is an adaptive that MI-induced LVH consistently damaged the compliance of the hearts and aggravated myocardial ischaemia. 15 Accumulating evidence from studies in patients and animal models indicated that cardiac hypertrophy after MI is not a compensatory but rather a maladaptive process. 16 Cardiac hypertrophy is not only a predictor but also a mediator of cardiovascular events predisposing patients to arrhythmias and heart failure. 17 Therefore, prevention of cardiac hypertrophy is considered as a novel strategy in the treatment of MI. 18 In particular, in the acute stage of the MI, the fatal arrhythmia ranks as one of the top cause of sudden death. 19, 20 Therefore, it is very important to diminish the underlying pro-arrhythmic hypertrophy after acute MI. Our group, together with the others, previously ischaemia/reperfusion injury, 6 the cellular and molecular mechanism of the protective role of HSF1 in the pathological cardiac remodelling led by direct ischaemia is still undetermined.
To our knowledge, this is the first report that the endogenous cardioprotective factor, HSF1, plays an essential role in the development of cardiac hypertrophy occurred in the early stage of MI. In the present study, we have 3 important findings. First, we identified HSF1 as an essential mediator of cardiac hypertrophy induced by hypoxic stimuli. Second, we found that the phosphorylation of HSF1 is required for the preservation of cardiac morphology and function in the early stage of MI in vivo. Third, the underlying mechanism by which HSF1 attenuated ischaemia-induced cardiac hypertrophy is associated with the blockage of the JAK2/STAT3 pathway. These data strongly suggested that maintaining of HSF1 at a higher level could prevent the occurrence of maladaptive cardiac hypertrophy and preserve the adaptation of the heart in response to ischaemia.
Our findings indicated that HSF1 is critically involved in the myocardial hypertrophy evoked by MI, implying a promising therapeutic potential of HSF1 in MI patients.
HSF1 was demonstrated as a key factor involved in the adaptive mechanism of transition from adaptive cardiac hypertrophy to maladaptive heart failure, 6 as well as an essential intrinsic factor protecting the cardiomyocytes against ischaemic injury via interacting with STAT3. 5, 7 In the present study, our first finding is that HSF1 phosphorylation was inhibited by the ischaemic stimulation. We observed that the phosphorylation level of HSF1 was reduced in the MIinduced cardiac hypertrophic infarct border zone area in vivo and hypoxia-treated NRCMs in vitro. On the basis of these observations, we concluded that the phosphorylation of HSF1 is a potential mechanism of the cardiac hypertrophy occurred in the early stage of MI. We also postulated that ischaemia can restrain the activation of HSF1 activation.
Although it is an adaptive change to maintain cardiac contractile function after acute MI, the hypertrophic response to the ischaemia is a potential attributor of the fatal arrhythmia in MI patients. 22 Here, we revealed that the deficiency of HSF1 exaggerated ischaemia-induced cardiac hypertrophy and dysfunction. Loss of HSF1 aug- LVAWd, left ventricular anterior wall end-diastolic thickness; EF, ejection fraction; LVIDd, left ventricular internal end-diastolic dimensions; HR, heart rate; LVESP, LV end-systolic pressure; LVEDP, LV end-diastolic pressure; max dp/dt, maximal contraction velocity; min dp/dt, maximal relaxation velocity. | 4301 in phosphorylation of Jak2 and STAT3. 9 Chronic activation of angiotensin II receptor 1 (AT1R) induced unregulated expression of the STAT3 gene, leading to nuclear accumulation of unphosphorylated form of STAT3, which significantly correlated with progression of cardiac hypertrophy. 10 Mechanical stretch activates the JAK/ STAT pathway in rat cardiomyocytes in vitro. 25 Therefore, various researches indicated that the activation of STAT3 was able to provoke cardiac hypertrophy both in vivo and in vitro. While some other data showed that STAT3 is a protective factor against ischaemia or I/R injury, STAT3 was fund to be crucial in cardiomyocyte resistance to inflammation and other acute injury and in pathogenesis of age-related heart failure. 26 STAT3 was also essential for postnatal capillary vasculature maintenance in the heart which protected heart from ischaemic injury and heart failure. 27 We ever reported a that granulocyte colony-stimulating factor stimulates phosphorylation at Y705 and association of Stat3 with HSF1 and therefore enhances transcriptional activity of HSF1, leading to the cardio-protection against I/R injury. 7 Based on these finding, it can be postulated that 
